Palmeri, Serena
Ponzano, Marta
Ivaldi, Federico
Signori, Alessio
Lapucci, Caterina
Casella, Valentina
Ferrò, Maria Teresa
Vigo, Tiziana
Inglese, Matilde
Mancardi, Giovanni Luigi
Uccelli, Antonio
Laroni, Alice http://orcid.org/0000-0001-5599-9788
Funding for this research was provided by:
agenzia italiana del farmaco, ministero della salute (Ricerca corrente)
Article History
Accepted: 26 October 2021
First Online: 11 December 2021
Declarations
:
: This work was supported by grants from the Italian Ministry of Health (Ricerca Corrente). The research by Alice Laroni on NK cells is funded by Fondazione Italiana Sclerosi Multipla, grant 271/18/F14.
: S. Palmeri reports no disclosures relevant to the article; M. Ponzano reports no disclosures relevant to the article; F. Ivaldi reports no disclosures relevant to the article; A. Signori reports no disclosures relevant to the article; C. Lapucci received research grants from Sanofi Genzyme and Roche; V. Casella reports no disclosures relevant to the article; M. T. Ferrò reports no disclosures relevant to the article; T. Vigo reports no disclosures relevant to the article; M. Inglese received research grants from NIH, NMSS, DOD, MS Society, FISM, INAIL, Italian Ministry of Health, European Union; received honoraria or consultation fees from Biogen, Roche, Merck, Genzyme, Novartis; G. L. Mancardi reports no disclosures relevant to the article; A. Uccelli received grants and contracts from FISM, Novartis, Biogen, Merck, Fondazione Cariplo, Italian Ministry of Health; received honoraria or consultation fees from Biogen, Roche, Teva, Merck, Genzyme, Novartis; A. Laroni received grants from Fondazione Italiana Sclerosi Multipla, Italian Ministry of Health, Italian Ministry of University; received honoraria or consultation fees from Biogen, Roche, Merck, Genzyme, Novartis.
: The study was approved by the Ethics Committee of IRCCS Ospedale Policlinico San Martino, Genova, protocol 190/12.
: Patients gave written consent to participate to the study.
: Not applicable
: Data are available upon reasonable request to the authors.
: Not applicable
: SP: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. MP: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data; additional contributions: graphic presentation. FI: Major role in the acquisition of data; revision of the manuscript for content. AS: Drafting/revision of the manuscript for content, including medical writing for content; study concept or design; analysis or interpretation of data. CL: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data. VC: Major role in the acquisition of data; revision of the manuscript for intellectual content. MTF: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data. TV: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; analysis or interpretation of data. MI: Drafting/revision of the manuscript for content, including medical writing for content. GLM: Drafting/revision of the manuscript for content, including medical writing for content. AU: Drafting/revision of the manuscript for content, including medical writing for content. AL: Drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. All authors read and approved the final submitted paper and agree to be accountable for this work.